The present disclosure provides methods and kits for treating and classifying individuals at risk of or suffering from a neurological dysfunction or disorder. In general, the individuals are treated and/or classified based on the presence of a loss-of-function mutation in nuclear DNA that encodes choline O-acetyltransferase (ChAT). Treatment involves the administration of a therapeutically effective amount of an acetylcholinesterase (AChE) inhibitor.
METHODS AND KITS FOR TREATING AND CLASSIFYING INDIVIDUALS AT RISK OF OR SUFFERING FROM A NEUROLOGICAL DYSFUNCTION OR DISORDER